Australia markets open in 9 hours 2 minutes

GSK Aug 2024 39.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
As of 10:59AM EDT. Market open.
Full screen
Previous close0.2000
Expiry date2024-08-16
Day's range0.2000 - 0.2000
Contract rangeN/A
Open interest669
  • Bloomberg

    European Stocks Decline as Investors Eye Nvidia, Rates Outlook

    (Bloomberg) -- European stocks dropped as investors turned their focus to this week’s earnings from artificial intelligence-bellwether Nvidia Corp. while monitoring for fresh clues on the outlook for interest rates.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe Turbulence‘It Felt Like We Had Crashed’: Singapore Air Passenger Describes Turbulence TerrorTesla Shareholder Group Slams Elon Musk’s $56 Billion Pay PackageHims Debuts $199 Weight-Loss Shots at 85% Discount to

  • Bloomberg

    GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay

    (Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe TurbulenceASML, TSMC Can Disable Chip Machines If China Invades TaiwanHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’Tesla Shareholder Group Slams Elon Musk’s

  • Reuters

    GSK whistleblower claims drugmaker cheated US government over Zantac cancer risk

    (Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."